Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1776705 | 0.87 | KMT2A (0.50) | L3MBTL1KMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL1776704 | 0.87 | KMT2A (0.50) | L3MBTL1KMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL19674474 | 0.87 | KMT2A (0.50) | L3MBTL1KMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL10755879 | 0.87 | KMT2A (0.50) | L3MBTL1KMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL10755871 | 0.87 | KMT2A (0.50) | L3MBTL1KMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL19731861 | 0.87 | KMT2A (0.42) | L3MBTL1KMT2AMEN1ALDH1A1KDM1A | |
| SCHEMBL12302297 | 0.82 | KMT2A (0.43) | L3MBTL1KMT2AMEN1KCNA5KDM1A | |
| SCHEMBL19726133 | 0.82 | KMT2A (0.48) | L3MBTL1KMT2AMEN1ALDH1A1KDM1A | |
| SCHEMBL5094203 | 0.81 | KMT2A (0.43) | L3MBTL1KMT2AMEN1KCNA5KDM1A | |
| SCHEMBL21708422 | 0.79 | L3MBTL1 (0.61) | L3MBTL1KMT2AMEN1ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336784-B2 | Methods for modular synthesis of N-glycans and arrays thereof | ACADEMIA SINICA (TW) | 2019-07-02 | — | — | US | disclosed |
| US-20170362265-A1 | METHODS FOR MODULAR SYNTHESIS OF N-GLYCANS AND ARRAYS THEREOF | ACADEMIA SINICA (TW) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362265-A1 | METHODS FOR MODULAR SYNTHESIS OF N-GLYCANS AND ARRAYS THEREOF | SIGLEC7, SIGLEC9, CD4 | L3MBTL1 1587/4885KMT2A 3272/4885MEN1 1327/4885 |
| US-10336784-B2 | Methods for modular synthesis of N-glycans and arrays thereof | SIGLEC7, SIGLEC9, CD4 | L3MBTL1 1587/4885KMT2A 3272/4885MEN1 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.